
    
      In this study SAH-patients are randomized to treatment based on international standard care
      (ICP/CPP guided therapy) or intracranial compliance (ICP mean wave amplitude) guided therapy
      in addition to ICP/CPP guided therapy. Main outcome variables are survival and neurological
      outcome after 3 and 12 months.
    
  